×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PCRX – pacira biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PCRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/3
08:00 am
pcrx
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/2
08:36 pm
pcrx
Does Pacira's ioveradeg Pilot Data and Smart Tip Clearance Change The Bull Case For Pacira (PCRX)? [Yahoo! Finance]
Low
Report
Does Pacira's ioveradeg Pilot Data and Smart Tip Clearance Change The Bull Case For Pacira (PCRX)? [Yahoo! Finance]
12/2
08:00 am
pcrx
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain
Low
Report
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain
11/26
05:38 pm
pcrx
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical [Yahoo! Finance]
Low
Report
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical [Yahoo! Finance]
11/26
04:01 pm
pcrx
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical
Low
Report
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical
11/18
01:18 pm
pcrx
Pacira BioSciences (NASDAQ:PCRX) had its "sell (d+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Pacira BioSciences (NASDAQ:PCRX) had its "sell (d+)" rating reaffirmed by analysts at Weiss Ratings.
11/17
08:06 am
pcrx
Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Low
Report
Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
11/11
09:51 am
pcrx
Pacira BioSciences gains as investor calls for full sales process [Seeking Alpha]
Low
Report
Pacira BioSciences gains as investor calls for full sales process [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/19
04:32 pm
pcrx
Form 4 Pacira BioSciences, Inc. For: Nov 17 Filed by: SLONIN JONATHAN
Medium
Report
Form 4 Pacira BioSciences, Inc. For: Nov 17 Filed by: SLONIN JONATHAN
11/17
10:26 am
pcrx
Form 144 Pacira BioSciences, Inc. Filed by: SLONIN JONATHAN
Low
Report
Form 144 Pacira BioSciences, Inc. Filed by: SLONIN JONATHAN
11/13
02:29 pm
pcrx
Form SCHEDULE 13G/A Pacira BioSciences, Inc. Filed by: RENAISSANCE TECHNOLOGIES LLC
Low
Report
Form SCHEDULE 13G/A Pacira BioSciences, Inc. Filed by: RENAISSANCE TECHNOLOGIES LLC
11/10
08:01 pm
pcrx
Form SCHEDULE 13D/A Pacira BioSciences, Inc. Filed by: Doma Perpetual Capital Management LLC
Medium
Report
Form SCHEDULE 13D/A Pacira BioSciences, Inc. Filed by: Doma Perpetual Capital Management LLC
11/10
10:02 am
pcrx
Form 144 Pacira BioSciences, Inc. Filed by: Cross Shawn
Medium
Report
Form 144 Pacira BioSciences, Inc. Filed by: Cross Shawn
11/6
04:16 pm
pcrx
Form 10-Q Pacira BioSciences, Inc. For: Sep 30
Medium
Report
Form 10-Q Pacira BioSciences, Inc. For: Sep 30
11/6
04:04 pm
pcrx
Form 8-K Pacira BioSciences, Inc. For: Nov 06
Medium
Report
Form 8-K Pacira BioSciences, Inc. For: Nov 06
11/3
05:41 pm
pcrx
Form 4 Pacira BioSciences, Inc. For: Oct 31 Filed by: Cross Shawn
Medium
Report
Form 4 Pacira BioSciences, Inc. For: Oct 31 Filed by: Cross Shawn
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/17
Pacira Biosciences Inc (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Northland Securities. They now have a $50.00 price target on the stock.
13.0%
3/23 Pacira Biosciences Inc (NASDAQ: PCRX) had its price target lowered by analysts at Piper Sandler from to . 6.6%
3/12 Form 4 Pacira BioSciences, Inc. For: Mar 11 Filed by: WINSTON ROY 6.0%
10/3 Pacira Biosciences Inc (NASDAQ: PCRX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 5.7%
2/10 Form SC 13G/A Pacira BioSciences, Inc. Filed by: BlackRock Inc. 5.0%
6/6 Form 4 Pacira BioSciences, Inc. For: Jun 05 Filed by: Brege Laura 4.6%
4/30 Pacira to Report First Quarter 2020 Financial Results on Thursday May 7, 2020 4.5%
4/24 Form DEF 14A Pacira BioSciences, Inc. For: Jun 08 3.6%
3/17 Pacira Biosciences Inc (NASDAQ: PCRX) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 3.5%
11/7 Pacira Biosciences Inc (NASDAQ: PCRX) had its "hold" rating re-affirmed by analysts at Cowen Inc. They now have a $41.00 price target on the stock. 3.3%
3/23 Pacira Biosciences Inc (NASDAQ: PCRX) had its price target lowered by analysts at Piper Sandler from to . 6.6%
3/12 Form 4 Pacira BioSciences, Inc. For: Mar 11 Filed by: WINSTON ROY 6.0%
10/3 Pacira Biosciences Inc (NASDAQ: PCRX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 5.7%
2/10 Form SC 13G/A Pacira BioSciences, Inc. Filed by: BlackRock Inc. 5.0%
6/6 Form 4 Pacira BioSciences, Inc. For: Jun 05 Filed by: Brege Laura 4.6%
4/30 Pacira to Report First Quarter 2020 Financial Results on Thursday May 7, 2020 4.5%
4/24 Form DEF 14A Pacira BioSciences, Inc. For: Jun 08 3.6%
3/17 Pacira Biosciences Inc (NASDAQ: PCRX) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 3.5%
11/7 Pacira Biosciences Inc (NASDAQ: PCRX) had its "hold" rating re-affirmed by analysts at Cowen Inc. They now have a $41.00 price target on the stock. 3.3%
TOP News Decliners
3/20
Pacira Biosciences Inc (NASDAQ: PCRX) was upgraded by analysts at SVB Leerink LLC from a "market perform" rating to an "outperform" rating.
-12.1%
3/23 Pacira Biosciences Inc (NASDAQ: PCRX) had its price target lowered by analysts at Royal Bank of Canada from $65.00 to $56.00. They now have an "outperform" rating on the stock. -9.6%
3/9 Pacira BioSciences to Present at the 2020 Barclays Global Healthcare Conference -6.8%
2/20 Pacira Biosciences Inc (NASDAQ: PCRX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -3.6%
8/8 Q2/2019 6/30/2019 EPS 0.410 ZacksConsensus 0.140 ActVsEst 0.270 - Beat -3.4%
9/24 Pacira BioSciences Set to Join S&P SmallCap 600 -3.3%
6/5 Form 4 Pacira BioSciences, Inc. For: Jun 03 Filed by: Scranton Richard -3.2%
2/21 Form 10-K Pacira BioSciences, Inc. For: Dec 31 -3.1%
9/30 Form SC 13G Pacira BioSciences, Inc. Filed by: INTEGRATED CORE STRATEGIES (US) LLC -3.0%
1/7 EXPAREL Achieves Primary and Key Secondary Endpoints in Phase 4 CHOICE Study in Cesarean Section Patients -2.9%
3/23 Pacira Biosciences Inc (NASDAQ: PCRX) had its price target lowered by analysts at Royal Bank of Canada from $65.00 to $56.00. They now have an "outperform" rating on the stock. -9.6%
3/9 Pacira BioSciences to Present at the 2020 Barclays Global Healthcare Conference -6.8%
2/20 Pacira Biosciences Inc (NASDAQ: PCRX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -3.6%
8/8 Q2/2019 6/30/2019 EPS 0.410 ZacksConsensus 0.140 ActVsEst 0.270 - Beat -3.4%
9/24 Pacira BioSciences Set to Join S&P SmallCap 600 -3.3%
6/5 Form 4 Pacira BioSciences, Inc. For: Jun 03 Filed by: Scranton Richard -3.2%
2/21 Form 10-K Pacira BioSciences, Inc. For: Dec 31 -3.1%
9/30 Form SC 13G Pacira BioSciences, Inc. Filed by: INTEGRATED CORE STRATEGIES (US) LLC -3.0%
1/7 EXPAREL Achieves Primary and Key Secondary Endpoints in Phase 4 CHOICE Study in Cesarean Section Patients -2.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: